title: [Recomendations for clinical use of food enriched phytosterols/phytostanols handling hypercholesterolemia].
abstract: Raised low-density lipoprotein cholesterol (LDLc) plasma concentration is a major risk factor for atherosclerotic cardiovascular disease. Despite international recommendations on hypercholesterolemia management the percentage of individuals with LDLc plasma concentration above goals according to their global cardiovascular risk remains high, and additional therapeutic strategies should be evaluated. Consumption of functional foods enriched with phytosterols (PSRs) and phytostanols (PSNs) reduces LDLc concentrations by 10% as average. Although recommended as part of any lipid-lowering diet in the first intervention step, PSRs/PSNs maintain their LDL reduction capacity when administered with lipid-lowering drugs; therefore, they can be also considered in some cases as an adjuvant to drug therapy. In this document we summarise the latest evidence regarding the LDL reducing effects of PSR/PSN supplementation, alone or as an add-on to hipolipemic drugs and the international recommendations of its clinical use.
authors.affiliation: Vascular Medicine and Metabolism Unit, Research Unit on Lipids and Atherosclerosis, Sant Joan University Hospital, IISPV, Rovira i Virgili University, Reus, España; Spanish Biomedical Research Network in Diabetes and Associated Metabolic Disorders (CIBERDEM), Barcelona, España. Electronic address: jordi.merino@urv.cat.
authors.forename: Jordi
authors.initials: J
authors.lastname: Merino
authors.affiliation: Vascular Medicine and Metabolism Unit, Research Unit on Lipids and Atherosclerosis, Sant Joan University Hospital, IISPV, Rovira i Virgili University, Reus, España; Spanish Biomedical Research Network in Diabetes and Associated Metabolic Disorders (CIBERDEM), Barcelona, España.
authors.forename: Luis
authors.initials: L
authors.lastname: Masana
authors.affiliation: Unidad de Medicina Interna, Hospital Universitario Fundación Alcorcón, Departamento de Medicina y Cirugía, Universidad Rey Juan Carlos, Alcorcón, Madrid, España.
authors.forename: Carlos
authors.initials: C
authors.lastname: Guijarro
authors.affiliation: Hospital Clínico Universitario de Valencia-INCLIVA, Departamento de Medicina, Universitat de València, CIBERDEM, Instituto de Salud Carlos III, Valencia, España.
authors.forename: Juan
authors.initials: J
authors.lastname: Ascaso
authors.affiliation: Hospital Universitario Puerta del Mar, Cádiz, España.
authors.forename: Manuel
authors.initials: M
authors.lastname: Lagares
authors.affiliation: Unidad de Lípidos y Laboratorio de Investigación Molecular, Hospital Universitario Miguel Servet, Instituto Aragonés de Ciencias de la Salud (I+CS), Zaragoza, España.
authors.forename: Fernando
authors.initials: F
authors.lastname: Civeira
mesh_terms: D000818:Animals; D050197:Atherosclerosis / Q000209:etiology / Q000517:prevention & control; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control; D008078:Cholesterol, LDL / Q000097:blood; D019587:Dietary Supplements; D005527:Food, Fortified; D006801:Humans; D006937:Hypercholesterolemia / Q000150:complications / Q000178:diet therapy* / Q000188:drug therapy; D000960:Hypolipidemic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D007391:International Cooperation; D010840:Phytosterols / Q000008:administration & dosage*; D012307:Risk Factors
chemical_list: D008078:Cholesterol, LDL; D000960:Hypolipidemic Agents; D010840:Phytosterols
keywords: Cardiovascular risk; Fitoesteroles; Fitostanoles; Hipercolesterolemia; Hypercholesterolaemia; Phytostanols; Phytosterols; Riesgo cardiovascular